Focused On-demand Library for Sp110 nuclear body protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9HB58

UPID:

SP110_HUMAN

Alternative names:

Interferon-induced protein 41/75; Speckled 110 kDa; Transcriptional coactivator Sp110

Alternative UPACC:

Q9HB58; B4DVI4; F5H1M1; Q14976; Q14977; Q53TG2; Q8WUZ6; Q9HCT8

Background:

The Sp110 nuclear body protein, also known as Interferon-induced protein 41/75, Speckled 110 kDa, and Transcriptional coactivator Sp110, plays a pivotal role in the immune system. It functions as a transcription factor and may act as a nuclear hormone receptor coactivator, enhancing the transcription of genes with retinoic acid response elements (RARE).

Therapeutic significance:

Sp110 is directly linked to Hepatic venoocclusive disease with immunodeficiency, a severe condition characterized by hypogammaglobulinemia, combined T and B-cell immunodeficiency, and absence of lymph node germinal centers. Understanding the role of Sp110 could open doors to potential therapeutic strategies for this immunodeficiency.